Failure of therapy · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…
It is very uncertain whether sealing using sealant materials changes failure of therapy compared with no treatment (very low certainty).
1 finding from 1 review
Safety of sealants and fluoride varnishes (adverse events) · Children and adolescents (general population, aged under 20 years)
1 finding from 1 review
Time taken to apply pit and fissure sealant or fluoride varnish · Children and adolescents (general population, aged under 20 years)
The review found no eligible studies for this question.
1 finding from 1 review
Progression of dentinal carious lesions into enamel or dentine · Children and adolescents (general population, aged under 20 years)
Resin-modified glass ionomer fissure sealant showed no clear difference in progression of dentinal carious lesions into enamel or dentine compared with fluoride varnish; GRADE not reported.
1 finding from 1 review
Number of visits to the dentist for repair of sealant or fluoride varnish application · Children and adolescents (general population, aged under 20 years)
The review found no eligible studies for this question.
1 finding from 1 review
Progression of dentinal carious lesions into enamel or dentine · Children and adolescents (general population, aged under 20 years)
The review found no eligible studies for this question.
1 finding from 1 review
Time taken to apply pit and fissure sealant or fluoride varnish · Children and adolescents (general population, aged under 20 years)
1 finding from 1 review
Changes in decayed, missing and filled (DMF) figures at whole-mouth level · Children and adolescents (general population, aged under 20 years)
1 finding from 1 review
Lung function(FEV1 or FVC L/min or % predicted) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to next exacerbation · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
1 finding from 1 review
Quality of life · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sputum bacterial density (CFU/mL) · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · adults and children with pulmonary exacerbation due to Pseudomonas aeruginosa
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.97 [0.89, 1.07]
Studies not reported
Low
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 0.93 [0.77, 1.11]
Studies not reported
Low
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 2.94 [0.12, 70.67]
Studies not reported
Low
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
RR 0.98 [0.76, 1.27]
Studies not reported
Moderate
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
RR 1.12 [0.97, 1.29]
Studies not reported
Low